Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 5, 2008, Pages 513-519

  Robertson, Sarah M ^a   Maldarelli, Frank ^b   Natarajan, Ven ^c   Formentini, Elizabeth ^d   Alfaro, Raul M ^e   Penzak, Scott R ^e  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HIV Drug Resistance Program   (United States)

^c SAIC FREDERICK INC   (United States)

^d Department of Critical Care Medicine ^*

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bupropion; CYP2B6; Drug interaction; Efavirenz; Induction; Metabolism

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; BIOLOGICAL MARKER; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; FEXOFENADINE; HYDROCORTISONE; MULTIDRUG RESISTANCE PROTEIN 1; RADAFAXINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; BENZOXAZINE DERIVATIVE; DRUG DERIVATIVE; N DEMETHYLASE; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ABSENCE OF SIDE EFFECTS; ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ERUPTION; DRUG HYDROXYLATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; MENTAL CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; VIVID DREAM; BLOOD; DELAYED RELEASE FORMULATION; DRUG EFFECT; DRUG INTERACTION; ENZYME INDUCTION; GENETIC VARIABILITY; GENETICS; HYDROXYLATION; METABOLISM; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; BUPROPION; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; GENETIC VARIATION; HUMANS; HYDROXYLATION; MALE; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; YOUNG ADULT;

EID: 62749169219     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318183a425     Document Type: Article

References (40)

1. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000;28:1176-1183.
2. Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999; 27:655-666.
3. Kharasch ED, Hoffer C, Whittington D, et al. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004;76: 250-269.
4. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33: 262-270.
5. Ramirez J, Innocenti F, Schuetz EG, et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004;32:930-936.
6. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
7. Hesse LM, von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001;29:100-102.
8. Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther. 2006;318:345-351.
9. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320:72-80.
10. Zyban® (bupropion hydrochloride) Sustained-Release Tablets, Prescribing Information [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
11. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000;28:1222-1230.
12. Zanger UM, Klein K, Saussele T, et al. Polymorphie CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743-759.
13. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007;8: 547-558.
14. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399-415.
15. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
16. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322-1326.
17. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5.
18. Wang D, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16:191-198.
19. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-36.
20. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001;11:447-458.
21. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004;78:1182-1187.
22. Kuráta Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther. 2002;72:209-219.
23. Sustiva® (efavirenz) Capsules and Tablets, Prescribing Information [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2007.
24. López-Cortés LF, Ruiz-Valderas R, Marín-Niebla A, et al. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J Acquir Immune Defic Syndr. 2005;39:551-556.
25. Barrett JS, Joshi AS, Chai M, et al. Population pharmacokinetic metaanalysis with efavirenz. Int J Clin Pharmacol Ther. 2002;40:507-519.
26. Poster M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2003;47: 130-137.
27. Faucette SR, Wang H, Hamilton GA, et al. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004;32:348-358.
28. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320:72-80.
29. Viramune® (nevirapine) Tablets, Prescribing Information [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2007.
30. Tegretol® (carbamazepine USP), Prescribing Information [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp; 2007.
31. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of Clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;77:553-559.
32. Palovaara S, Pelkonen O, Jouko U, et al. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther. 2005;74: 326-333.
33. Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2007;81:69-75.
34. Turpeinen M, Koivuviita N, Tolonen A, et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol. 2007;64:165-173.
35. Johnston JA, Fiedler-Kelly J, Glover ED, et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res. 2001;3:131-140.
36. Johnston AJ, Ascher J, Leadbetter R, et al. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs. 2002;62: 11-24.
37. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther. 2005;27:1685-1695.
38. Loboz KK, Gross AS, Williams KM, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006;80:75-84.
39. Haynes K, Faucette SR, Lindley CM, et al. Evaluation of bupropion hydroxylation as a probe of cytochrome P450 2B6 activity in cultured human hepatocytes. Paper presented at: American College of Clinical Pharmacy; October 20-23, 2002; Savannah, GA. Abstract 165.
40. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73:20-30.